Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock went on an upward path that rose over 1.04% on Thursday, amounting to a one-week price decrease of less than -5.72%.
Over the last 12 months, ACAD stock dropped by -34.49%. The one-year Acadia Pharmaceuticals Inc stock forecast points to a potential upside of 38.35. The average equity rating for ACAD stock is currently 1.79, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $2.57 billion, with 164.65 million shares outstanding and 164.62 million shares in the current float. Compared to the average trading volume of 1.70M shares, ACAD stock reached a trading volume of 2942713 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Acadia Pharmaceuticals Inc [ACAD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $25.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.79. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Acadia Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on August 07, 2024. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on June 27, 2024, representing the official price target for Acadia Pharmaceuticals Inc stock. Previously, the target price had yet another drop from $36 to $32, while Needham kept a Buy rating on ACAD stock. On March 12, 2024, analysts decreased their price target for ACAD shares from 39 to 25.
The Average True Range (ATR) for Acadia Pharmaceuticals Inc is set at 0.56, with the Price to Sales ratio for ACAD stock in the period of the last 12 months amounting to 2.88. The Price to Book ratio for the last quarter was 4.97, with the Price to Cash per share for the same quarter was set at 3.02. Price to Free Cash Flow for ACAD in the course of the last twelve months was 31.91 with Quick ratio for the last quarter at 1.95.
ACAD Stock Performance Analysis:
Acadia Pharmaceuticals Inc [ACAD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.72. With this latest performance, ACAD shares dropped by -1.71% in over the last four-week period, additionally sinking by -14.95% over the last 6 months – not to mention a drop of -34.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 40.89, with the RSI for the last a single of trading hit 36.77, and the three-weeks RSI is set at 43.19 for Acadia Pharmaceuticals Inc [ACAD]. The present Moving Average for the last 50 days of trading for this stock 16.64, while it was recorded at 15.89 for the last single week of trading, and 19.83 for the last 200 days.
Insight into Acadia Pharmaceuticals Inc Fundamentals:
Acadia Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.95 and a Current Ratio set at 2.16.
Acadia Pharmaceuticals Inc [ACAD] Institutonal Ownership Details
There are presently around $99.98%, or 100.52%% of ACAD stock, in the hands of institutional investors. The top three institutional holders of ACAD stocks are: BAKER BROS. ADVISORS LP with ownership of 42.88 million shares, which is approximately 26.0185%. VANGUARD GROUP INC, holding 13.71 million shares of the stock with an approximate value of $$222.82 million in ACAD stocks shares; and VANGUARD GROUP INC, currently with $$222.75 million in ACAD stock with ownership which is approximately 8.3178%.
